We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Branched amino acids as potential biomarkers in metabolic syndrome patients and as hypolipidemic compounds.
- Authors
Alqaraleh, Moath; Kasabri, Violet; Farha, Rana Abu; Naffa, Randa G.; Yousef, Israa; Aljaafreh, Ahmad
- Abstract
Background and aims: Metabolic syndrome (MetS) and lipid abnormalities can increase the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aims of this study were to assess branched-chain amino acids (BCAAs) levels in MetS patients and to evaluate the effects of these acids on lipid profile abnormalities. Material and Methods: A cross-sectional study design comprising 30 normoglycemic lean subjects, 30 MetS patients, and 30 MetS-pre/T2DM patients was conducted to measure the BCAA levels for each of these groups. Then, an in vivo evaluation of BCAA hypolipidemic activity using Triton WR-1339-induced hyperlipidemia was conducted in rats. Results: The BCAAs plasma levels showed a substantially significant increase in both MetS and MetS-pre/T2DM groups compared with lean normoglycemic controls. Furthermore, BCAAs in Triton WR-1339 treated rats could exert fenofibrate-like pronounced TC, TG, and LDL-C reductions but marked the HDL-C enhancements significantly. Conclusion: MetS is associated with the high plasma level of BCAAs, indicative of a putative predictive/prognostic value with respect to MetS patients. Moreover, BCAAs supplementation may serve as a potential novel therapeutic agent for the treatment of hyperlipidemia.
- Subjects
THERAPEUTIC use of amino acids; METABOLIC syndrome diagnosis; TYPE 2 diabetes; CARDIOVASCULAR diseases; HYPERLIPIDEMIA treatment
- Publication
EurAsian Journal of Biosciences, 2019, Vol 13, Issue 2, p2233
- ISSN
1307-9867
- Publication type
Article